The Legal Intelligencer | Analysis
By Max Mitchell | October 22, 2019
The term "nuclear" verdict has a bit of a fluid meaning. Many who spoke with The Legal described it as an award that is significantly higher than would be expected given the injuries in the case, rather than a term indicating any particular threshold.
By Amanda Bronstad | October 21, 2019
Paul Hanly of New York's Simmons Hanly Conroy said co-lead counsel were finalizing details of a deal until 1 a.m. on Monday.
By Amanda Bronstad | October 18, 2019
About half the 22 lawyers proposed to lead the lawsuits are women. One of them, Ellen Relkin, said that her daughter, who is a teacher, told her "there was a kid literally charging his Juul in the classroom."
By Jack Newsham | October 18, 2019
The additions from Ahmuty, Demers & McManus boost Cullen and Dykman's tristate tort capabilities.
By Amanda Bronstad | October 18, 2019
Lawyers and legal experts list a host of reasons for larger jury awards such as the $8 billion Risperdal verdict, including evolving societal norms, changes in the plaintiffs bar and the actions of defendants.
By Amanda Bronstad | October 17, 2019
Lawyers and legal experts list a host of reasons for larger jury awards such as the $8 billion Risperdal verdict last week, including evolving societal norms, changes in the plaintiffs bar and the actions of defendants.
By Amanda Bronstad | October 17, 2019
Lawyers and legal experts list a host of reasons for larger jury awards such as the $8 billion Risperdal verdict last week, including evolving societal norms, changes in the plaintiffs bar and the actions of defendants.
The Legal Intelligencer | News
By Amanda Bronstad | October 17, 2019
Lawyers and legal experts list a host of reasons for larger jury awards such as the $8 billion Risperdal verdict in Philadelphia last week, including evolving societal norms, changes in the plaintiffs bar and the actions of defendants.
By Amanda Bronstad | October 15, 2019
Tuesday's ruling found that the plaintiff, who alleged she got ovarian cancer in 2012 from using Johnson & Johnson's baby powder, had no jurisdiction to bring her case in Missouri under the U.S. Supreme Court's Bristol-Myers ruling.
By Amanda Bronstad | October 15, 2019
Tuesday's ruling by the Missouri Court of Appeals found that the Virginia plaintiff, Lois Slemp, who alleged she got ovarian cancer in 2012 from using Johnson & Johnson's baby powder, had no jurisdiction to bring her case in Missouri under the U.S. Supreme Court's Bristol-Myers ruling.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law.com celebrates the California law firms and legal departments driving the state's dynamic legal landscape.
The Texas Lawyer honors attorneys and judges who have made a remarkable difference in the legal profession in Texas.
CORE RESPONSIBILITIES AND TASKS: Reporting to the Senior Vice President, Chief Legal Officer &...
Yale New Haven Health seeks a dynamic and collaborative executive to serve as its Vice President, Labor Strategy and Senior Associate Genera...
Nestled in the heart of Northern California Wine Country, Sonoma County is the largest county in the North Bay region of the San Francisco B...